Prophylactic Pharmacotherapy for Migraine Headaches

ABSTRACT

Migraine therapeutics are pharmacological, including acute and preventive, nonpharmacological and/or both. Preventive pharmacological strategies serendipitously were discovered to be effective and include drugs from various pharmacological classes (e.g., β-adrenergic blocker, anticonvulsant, tricyclic antidepressants, serotonin receptor antagonist). Converging level I evidence and clinical experience support the use of the antidepressant amitriptyline, the anticonvulsants divalproex and topiramate, and the β-adrenergic blockers propranolol, timolol, and metoprolol in migraine prevention. Other options for migraine prophylaxis exist, but the level of evidence in support of their use is not as robust. All of these drugs have varying degrees of adverse effects, some of which can limit their use. Balancing potential efficacy with risk of adverse effects, addressing patients' expectations and desires, complying with management recommendations, adequate follow up, and accurate assessment of treatment goals are key to migraine prevention. Finally, future migraine-preventive drugs likely will target migraine mechanisms more specifically, which undoubtedly will enhance the therapeutic index.

Migraine - prevention - pharmacology - mechanisms - hyperexcitability - cortical spreading depression

REFERENCES

• 1 Ramadan N M. Epidemiology and impact of migraine.  Continuum. 2003a;  9-24
• 2 Murray C J, Lopez A D. Global mortality, disability, and the contribution of risk factors: global burden of disease study.  Lancet. 1997;  349 1436-1442
• 3 Ramadan N M. Prophylactic migraine therapy: mechanisms and evidence.  Curr Pain Headache Rep. 2004;  8 91-95
• 4 Welch K M, D'Andrea G, Tepley N, Barkley G, Ramadan N M. The concept of migraine as a state of central neuronal hyperexcitability.  Neurol Clin. 1990;  8 817-828
• 5 Welch K MA. Contemporary concepts of migraine pathogenesis.  Neurology. 2003;  61(suppl 4) S2-S8
• 6 Ramadan N M, Silberstein S D, Freitag F G, Gilbert T T, Frishberg B M. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for the prevention of migraine. U.S. Headache Consortium, 2000. Available at: http://www.aan.com/professionals/practice/pdfs/gl0090.pdf Accessed May 30, 2005
• 7 Bigal M E, Krymchantowski A V, Rapoport A M. Prophylactic migraine therapy: emerging treatment options.  Curr Pain Headache Rep. 2004;  8 178-184
• 8 Elkind A H, Webster C, Herbertson R K. Efficacy of guafacine in a double-blind parallel study for migraine prophylaxis.  Cephalalgia. 1989;  9(suppl 10) 369-370
• 9 Saper J R, Lake III A E, Cantrell D T, Winner P K, White J R. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.  Headache. 2002;  42 470-482
• 10 Kang Y J, Eisenach J C. Intrathecal clonidine reduces hypersensitivity after nerve injury by a mechanism involving spinal m4 muscarinic receptors.  Anesth Analg. 2003;  96 1403-1408
• 11 Bender W I. ACE inhibitors for the prophylaxis of migraine headaches.  Headache. 1995;  35 470-471
• 12 Schrader H, Stovner L J, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo controlled, crossover study.  BMJ. 2001;  322 19-22
• 13 Paterna S, Di Pasquale P, D'Angelo A et al.. Angiotensin converting enzyme gene deletion polymorphism determines and increase in frequency of migraine attacks in patients suffering from migraine without aura.  Eur Neurol. 2000;  43 133-136
• 14 Tronvik E, Stovner L J, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.  JAMA. 2003;  289 65-69
• 15 Ziegler D K, Hurwitz A, Hassanein R S, Kodanaz H A, Preskorn S H, Mason J. Migraine prophylaxis: a comparison of propranolol and amitriptyline.  Arch Neurol. 1987;  44 486-489
• 16 Mathew N T. Prophylaxis of migraine and mixed headache: a randomized controlled study.  Headache. 1981;  21 105-109
• 17 Ozyalcin S N, Talu G K, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine.  Headache. 2005;  45 144-152
• 18 Krymchantowski A V, Bigal M E, Moreira P F. New and emerging prophylactic agents for migraine.  CNS Drugs. 2002;  16 611-634
• 19 Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study.  Cephalalgia. 1997;  17 103-108
• 20 Freitag F G, Collins S D, Carlson H A et al.. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.  Neurology. 2002;  58 1652-1659
• 21 Brandes J L, Saper J R, Diamond M et al.. Topiramate for migraine prevention: a randomized controlled trial.  JAMA. 2004;  291 965-973
• 22 Silberstein S D, Neto W, Schmitt J, Jacobs D. MIGR-001 Study Group . Topiramate in migraine prevention: results of a large controlled trial.  Arch Neurol. 2004;  61 490-495
• 23 Shank R P, Gardocki J F, Streeter A J, Maryanoff B E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action.  Epilepsia. 2000;  41(suppl 1) S3-S9
• 24 Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study.  Clin Ter. 2000;  151 145-148
• 25 Mathew N T, Rapoport A, Saper J et al.. Efficacy of gabapentin in migraine prophylaxis.  Headache. 2001;  41 119-128
• 26 Brown J P, Dissanayake V U, Briggs A R, Milic M R, Gee N S. Isolation of the [3H]gabapentin-binding protein/alpha 2 delta Ca²⁺ channel subunit from porcine brain: development of a radioligand binding assay for alpha 2 delta subunits using [3H]leucine.  Anal Biochem. 1998;  255 236-243
• 27 Fink K, Dooley D J, Wolfgang P M et al.. Inhibition of neuronal Ca²⁺ influx by gabapentin and pregabalin in the human neocortex.  Neuropharmacology. 2002;  42 229-236
• 28 Eckstein-Ludwig U, Fei J, Schwarz W. Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs.  Br J Pharmacol. 1999;  128 92-102
• 29 Saper J S, Silberstein S, Somogyi M, McCague K. Efficacy and safety of oxcarbazepine in patients with migraine headaches: a multicenter, double-blind, randomized, placebo-controlled study [abstract]. Poster presented at the Annual Meeting of The American Academy of Neurology New Orleans, LA; Poster session April 14, 2005 (P05.152)
• 30 Steiner T J, Findley L J, Yuen A W. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.  Cephalalgia. 1997;  17 109-112
• 31 D'Andrea G, Granella F, Cadaldini M, Manzoni G C. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study.  Cephalalgia. 1999;  19 64-66
• 32 Ramadan N M, Schultz L L, Gilkey S J. Migraine prophylactic drugs: proof of efficacy, utilization and cost.  Cephalalgia. 1997;  17 73-80
• 33 Pietrobon D. Calcium channels and channelopathies of the central nervous system.  Mol Neurobiol. 2002;  25 31-50
• 34 Omote K, Iwasaki H, Kawamata M, Satoh O, Namiki A. Effects of verapamil on spinal anesthesia with local anesthetics.  Anesth Analg. 1995;  80 444-448
• 35 Akerman S, Williamson D J, Goadsby P J. Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism.  Br J Pharmacol. 2003;  140 558-566
• 36 Wallace M S. Calcium and sodium channel antagonists for the treatment of pain.  Clin J Pain. 2000;  16(suppl 2) S80-S85
• 37 Knight Y E, Bartsch T, Kaube H, Goadsby P J. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine?.  J Neurosci. 2002;  22 RC213
• 38 Ophoff R A, Terwindt G M, Vergouwe M N et al.. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca²⁺ channel gene CACNL1A4.  Cell. 1996;  87 543-552
• 39 Kors E E, van den Maagdenberg A M, Plomp J J, Frants R R, Ferrari M D. Calcium channel mutations and migraine.  Curr Opin Neurol. 2002;  15 311-316
• 40 van den Maagdenberg A M, Pietrobon D, Pizzorusso T et al.. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression.  Neuron. 2004;  41 701-710
• 41 Klapper J, Mathew N T, Abu-Shakra S. Donepezil vs. propranolol for migraine prevention: results of a randomized, controlled, double-blind, double-dummy clinical trial [abstract]. Poster presented at the annual meeting of the American Academy of Neurology New Orleans, LA; Poster session April 14, 2005 (P05.155)
• 42 Sandor P S, Afra J. Nonpharmacologic treatment of migraine.  Curr Pain Headache Rep. 2005;  9 202-205
• 43 Boska M D, Welch K M, Barker P B, Nelson J A, Schultz L. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes.  Neurology. 2002;  58 1227-1233
• 44 Ramadan N M, Halvorson H, Vande-Linde A, Levine S R, Helpern J A, Welch K M. Low brain magnesium in migraine.  Headache. 1989;  29 590-593
• 45 Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study.  Cephalalgia. 1996;  16 257-263
• 46 Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial.  Neurology. 1998;  50 466-470
• 47 Sandor P S, Di Clemente L, Coppola G et al.. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.  Neurology. 2005;  64 713-715
• 48 Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial.  Headache. 2004;  44 885-890
• 49 Sandor P S, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials.  Headache. 2000;  40 30-35
• 50 Ciancarelli I, Tozzi-Ciancarelli M G, Di Massimo C, Marini C, Carolei A. Urinary nitric oxide metabolites and lipid peroxidation by-products in migraine.  Cephalalgia. 2003;  23 39-42
• 51 Tozzi-Ciancarelli M G, De Matteis G, Di Massimo C, Marini C, Ciancarelli I, Carolei A. Oxidative stress and platelet responsiveness in migraine.  Cephalalgia. 1997;  17 580-584
• 52 Sangiorgi S, Mochi M, Riva R et al.. Abnormal platelet mitochondrial function in patients affected by migraine with and without aura.  Cephalalgia. 1994;  14 21-23
• 53 Ashkenazi A, Silberstein A D. Botulinum toxin and other new approaches to migraine therapy.  Annu Rev Med. 2004;  55 505-518
• 54 Blumenfeld A. Botulinum toxin type A for the treatment of headache: pro.  Headache. 2004;  44 825-830
• 55 Welch K MA. Botulinum toxin type A for the treatment of headache: con.  Headache. 2004;  44 831-833
• 56 Elkind A H, Friedman A P, Bachman A, Siegelman S S, Sacks O W. Silent retroperitoneal fibrosis associated with methysergide therapy.  JAMA. 1968;  206 1041-1044
• 57 Curran D A, Lance J W. Clinical trials of methysergide and other preparations in the management of migraine.  J Neurol Neurosurg Psychiatry. 1964;  27 463-469
• 58 Terron J A, Bouchelet I, Hamel E. 5-HT7 receptor mRNA expression in human trigeminal ganglia.  Neurosci Lett. 2001;  302 9-12
• 59 Pittler M H, Ernst E. Feverfew for preventing migraine.  Cochrane Database Syst Rev. 2004;  (1) CD002286
• 60 Reuter U, Chiarugi A, Bolay H, Moskowitz M A. Nuclear factor-kappaB as a molecular target for migraine therapy.  Ann Neurol. 2002;  51 507-516
• 61 Lipton R B, Gobel H, Einhaupl K M, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine.  Neurology. 2004;  63 2240-2244
• 62 Wang G J, Shum A Y, Lin Y L et al.. Calcium channel blockade in vascular smooth muscle cells: major hypotensive mechanism of S-petasin, a hypotensive sesquiterpene from petasites formosanus.  J Pharmacol Exp Ther. 2001;  297 240-246
• 63 Eaton J. Butterbur, herbal help for migraine.  Natural Pharmacy. 1998;  2 23-24